ArticleCancer immunology, immunotherapy : CII2025

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.

Ray Manneh Kopp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.